Meluzio Michael Vincent reported option exercise involving 13,647 shares of Cue Biopharma, Inc. at $0.00 for $0 on Aug 13, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
VP, Prin. Accounting Officer
VP, Prin. Accounting Officer
Filed Aug 17, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
13,647Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
54,589Direct
Trade date
Aug 13, 2026Option exercise
Filed
Aug 17, 2026, 6:19 PM ET4-day reporting delay
Accession
0002138368-26-000007Code M · Transaction 1191
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 13, 2026Option exercise13,647$0.00$0Trade 1195
Aug 13, 2026Sell1,519$29.37−$44,613.03Trade 1192
Aug 13, 2026Sell4,106$30.35−$124,617.10Trade 1193
Aug 13, 2026Sell3$31.13−$93.39Trade 1194
5 transaction rows in this filing. Joint filers share the same rows.

CUE price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CUE · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +2.5%1w ago −2.8%1d ago −2.8%
Returns since7d −16%30d +24%90d −42%180d1y

Footnotes in full

F1: The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the reporting person. F2: The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $28.97 to $29.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades. F3: The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $29.99 to $30.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades. F4: The performance stock units ("PSU") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 13, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days.